• Mutation; VGNC; VGNC:46802; SRGAP3; Simple; p.Val850fs (c.2548dupG); Zygosity=Heterozygous (PubMed=31175136).
  

PubMed=21908323; DOI=10.1177/1040638711408064
O'Donoghue L.E., Rivest J.P., Duval D.L.
Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation.
J. Vet. Diagn. Invest. 23:780-785(2011)

PubMed=22916246; DOI=10.1371/journal.pone.0043355; PMCID=PMC3420908
Maeda J., Yurkon C.R., Fujisawa H., Kaneko M., Genet S.C., Roybal E.J., Rota G.W., Saffer E.R., Rose B.J., Hanneman W.H., Thamm D.H., Kato T.A.
Genomic instability and telomere fusion of canine osteosarcoma cells.
PLoS ONE 7:E43355-E43355(2012)

PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)

PubMed=36099278; DOI=10.1371/journal.pone.0274383; PMCID=PMC9469990
Megquier K., Turner-Maier J., Morrill K., Li X., Johnson J., Karlsson E.K., London C.A., Gardner H.L.
The genomic landscape of canine osteosarcoma cell lines reveals conserved structural complexity and pathway alterations.
PLoS ONE 17:E0274383-E0274383(2022)